A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary *UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot Campaign in North Carolina
View HTML
Toggle Summary CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®
View HTML
Toggle Summary Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016
-- Study Advancing Genomic-Level Understanding of Hürthle Lesions Also Presented --
View HTML
Toggle Summary CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Second paragraph, first sentence of release should include Dr. Jose Herazo-Maya , currently Director of Interstitial Lung Disease Program
View HTML
Toggle Summary CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
Greater than 50 Percent Reduction in Patients Classified as Low Risk for Lung Cancer SAN FRANCISCO --(BUSINESS WIRE)-- Correcting quote attribution in the third paragraph of release issued Nov. 1, 2017 . The corrected release reads: VERACYTE ANNOUNCES PRESENTATION OF NEW CLINICAL UTILITY DATA AT
View HTML
Toggle Summary Data Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2016 /PRNewswire/ --  Veracyte, Inc.  ( NASDAQ : VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies
View HTML
Toggle Summary Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"
-- Findings suggest that test's use reduces invasive lung-cancer diagnostic procedures by 28 percent and is cost-effective --
View HTML
Toggle Summary Data from Multiple Studies Evaluating Veracyte's Genomic Classifiers for Lung Cancer and Idiopathic Pulmonary Fibrosis to Be Presented at ATS 2016
SOUTH SAN FRANCISCO, Calif. , May 3, 2016 /PRNewswire/ -- Veracyte, Inc. ( NASDAQ : VCYT) today announced that data from multiple studies supporting the company's genomic tests to resolve ambiguity in pulmonary disease diagnosis will be presented at the American Thoracic Society (ATS) 2016
View HTML
Toggle Summary Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
Additional Data Presented on Development Of Company's Next-Generation Afirma Genomic Sequencing Classifier
View HTML